Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China.
Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China.
Clin Chim Acta. 2017 Aug;471:55-61. doi: 10.1016/j.cca.2017.05.022. Epub 2017 May 16.
CXC chemokine ligand-12 (CXCL12), a member of the CXC chemokine subfamily, is involved in both focal angiogenesis and inflammatory reactions. We examined serum CXCL12 concentration in intracerebral hemorrhage (ICH) patients and its correlation to stroke severity and outcome.
The study was carried out on 105 ICH patients on 105 healthy controls. Serum samples were at admission obtained to measure CXCL12 concentrations. The National Institutes of Health Stroke Scale (NIHSS) and hematoma volume were recorded to assess stroke severity.
As compared to the controls, CXCL12 concentrations were significantly increased in the patients. Also, non-survivors within 6months and patients with an unfavorable outcome (modified Rankin Scale score>2) at 6months had higher CXCL12 concentrations than other remaining ones. CXCL12 concentrations had positive correlation with NIHSS scores and hematoma volume. Serum CXCL12 significantly discriminated patients at risk of 6-month mortality and 6-month unfavorable outcome under receiver operating characteristic curve. Moreover, serum CXCL12 was independently associated with the mortality, overall survival and unfavorable outcome.
Serum CXCL12 concentrations are enhanced after ICH and CXCL12 in serum has the potential to reflect severity and prognosis following hemorrhagic stroke.
CXC 趋化因子配体-12(CXCL12)是 CXC 趋化因子亚家族的成员,参与局灶性血管生成和炎症反应。我们检测了脑出血(ICH)患者血清中 CXCL12 浓度及其与卒中严重程度和预后的关系。
该研究纳入了 105 名 ICH 患者和 105 名健康对照者。入院时采集血清样本以测量 CXCL12 浓度。记录国立卫生研究院卒中量表(NIHSS)评分和血肿体积以评估卒中严重程度。
与对照组相比,患者血清中 CXCL12 浓度显著升高。此外,6 个月内死亡的非幸存者和 6 个月时预后不良(改良 Rankin 量表评分>2)的患者的 CXCL12 浓度高于其他患者。CXCL12 浓度与 NIHSS 评分和血肿体积呈正相关。血清 CXCL12 在受试者工作特征曲线下可显著区分 6 个月时死亡和预后不良的患者。此外,血清 CXCL12 与死亡率、总生存率和预后不良独立相关。
ICH 后血清 CXCL12 浓度升高,血清 CXCL12 具有反映出血性卒中后严重程度和预后的潜力。